FGFR1 and pancreatic neoplasm: Here, we reported, for the first time, that combined treatment with FGFR1 and PLK1 inhibitors evokes synergistic cytotoxic activity in KRAS‐mutant lung and pancreatic cancer models in vitro and in vivo.